News | April 16, 2014

Navidea Provides Update on European Marketing Authorization Application for Lymphoseek

April 16, 2014 — Navidea Biopharmaceuticals Inc. held an update meeting with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the pending Marketing Authorization Application (MAA) of Lymphoseek (technetium Tc 99m tilmanocept) Injection. Lymphoseek is a lymphatic mapping agent designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer. As part of the MAA review process, Navidea presented Oral Explanations to the CHMP relating to open questions in the Lymphoseek MAA. At the conclusion of the meeting, the CHMP informed Navidea that the committee would continue with its review of the MAA. Navidea believes the course of the review continues to be supportive of its market development plans and outlook for material revenue generation in Europe beginning in 2015, as previously disclosed.

Based on feedback received at the meeting, Navidea believes that the CHMP has found the safety and efficacy data submitted in the MAA for breast cancer and melanoma to be acceptable. The CHMP will now focus its review on the remaining areas of product specifications unique to the European application and on data from the Phase 3 study in head and neck cancer. During this process, the MAA remains active but the review clock will continue to be stopped while Navidea works with the CHMP to address these remaining areas.

The Lymphoseek MAA is supported by a comprehensive, multi-trial clinical program including two Phase 3 studies of Lymphoseek (NEO3-05 and NEO3-09) performed in patients with either breast cancer or melanoma and a third Phase 3 study (NEO3-06), in patients with head and neck cancer, contributing to a safety database of more than 550 patients. The MAA is based on the same pivotal efficacy and safety data package provided in the U.S. New Drug Application (NDA) and two supplemental NDA (sNDA) submissions. The U.S. Food and Drug Administration (FDA) approved Lymphoseek in the United States in 2013 for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. Lymphoseek was also granted Fast Track designation and Priority Review for one of its sNDAs focused on sentinel lymph node detection in patients with head and neck cancer, with an upcoming Prescription Drug User Fee Act (PDUFA) target date of June 16, 2014. The second sNDA has a PDUFA target date of Oct.16, 2014.

For more information: www.navidea.com

 

Related Content

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital.

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital. Photo courtesy of Thorsten Mohr/Saarland University

News | Prostate Cancer | November 28, 2019
November 28, 2019 — Reports of new cancer treatments
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
Philips Medical System is recalling its older Forte Gamma Camera SPECT imaging systems due to the possibility of the detectors falling off of the unit onto the patient. The two gamma cameras can bee seen in this photo on either side of the patient bed. These can be rotated above the patient.

Philips Medical System is recalling its older Forte Gamma Camera SPECT imaging systems due to the possibility of the detectors falling off of the unit onto the patient. The two gamma cameras can be seen in this photo on either side of the patient bed. These can be rotated above the patient.

Feature | Nuclear Imaging | November 05, 2019 | Dave Fornell, Editor
November 5, 2019 — Philips Medical System is recalling the Forte Gamma Camera System due to the potential for the 660
 Phoenix’s fusion neutron generation technology.
News | Radiopharmaceuticals and Tracers | October 28, 2019
October 28, 2019 — Phoenix LLC and Shine Medical Technologies LLC, nuclear technology companies focused on near-term
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along
A 3-D printed tungsten pre-clinical X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten pre-clinical X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | September 04, 2019 | By Steve Jeffery
In ...